Protara Therapeutics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Protara Therapeutics, Inc. (TARA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $4.53 per share for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-08.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2025-05-08
- Protara Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $4.53.
- Protara Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2019-03-31 was $2.66, a 0.38% increase year-over-year.
- Protara Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2018-03-31 was $2.65, a 29.27% increase year-over-year.
- Protara Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2017-03-31 was $2.05, a 69.31% decline year-over-year.
- Protara Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $2.04.
- Protara Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2019 was $106.32, a 3973.56% increase from fiscal 2018.
- Protara Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2018 was $2.61, a 31.16% increase from fiscal 2017.
- Protara Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2017 was $1.99, a 72.01% decline from fiscal 2016.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2025-03-31 | $4.53 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $2.04 10-K · filed 2025-03-05 | |||
| 2019-12-31 | $106.32 10-K · filed 2020-03-20 | |||
| 2019-09-30 | $2.66 10-Q · filed 2019-10-31 | |||
| 2019-06-30 | $2.66 10-Q · filed 2019-08-07 | |||
| 2019-03-31 | $2.66 10-Q · filed 2019-05-08 | |||
| 2018-12-31 | $2.61 10-K · filed 2019-03-13 | |||
| 2018-09-30 | $2.61 10-Q · filed 2018-11-07 | |||
| 2018-06-30 | $2.65 10-Q · filed 2018-08-07 | |||
| 2018-03-31 | $2.65 10-Q · filed 2018-05-09 | |||
| 2017-12-31 | $1.99 10-K · filed 2018-03-14 | |||
| 2017-06-30 | $2.00 10-Q · filed 2017-08-07 | |||
| 2017-03-31 | $2.05 10-Q · filed 2017-05-10 | |||
| 2016-12-31 | $7.11 10-K · filed 2019-03-13 | |||
| 2016-09-30 | $6.90 10-Q · filed 2016-11-07 | |||
| 2016-06-30 | $6.77 10-Q · filed 2016-08-08 | |||
| 2016-03-31 | $6.68 10-Q · filed 2016-05-09 | |||
| 2015-12-31 | $13.52 10-K · filed 2016-03-14 | |||
| 2015-09-30 | $12.68 10-Q · filed 2015-11-12 | |||
| 2015-06-30 | $12.29 10-Q · filed 2015-08-13 | |||
| 2015-03-31 | $10.61 10-Q · filed 2015-05-13 | |||
| 2014-12-31 | $5.94 10-K · filed 2015-03-20 | |||
| 2014-09-30 | $4.92 10-Q · filed 2014-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |